21 October 2023 in Nature Communications
Organoids are engineered 3D miniature tissues that are defined by their organ-like structures, which drive a fundamental understanding of human development. However, current organoid generation methods are associated with low production throughputs and poor control over size and function including due to organoid merging, which limits their clinical and industrial translation. Here, we present a microfluidic platform for the mass production of lumenogenic embryoid bodies and functional cardiospheres. Specifically, we apply triple-jet in-air microfluidics for the ultra-high-throughput generation of hollow, thin-shelled, hydrogel microcapsules that can act as spheroid-forming bioreactors in a cytocompatible, oil-free, surfactant-free, and size-controlled manner. Uniquely, we show that microcapsules generated by in-air microfluidics provide a lumenogenic microenvironment with near 100% efficient cavitation of spheroids. We demonstrate that upon chemical stimulation, human pluripotent stem cell-derived spheroids undergo cardiomyogenic differentiation, effectively resulting in the mass production of homogeneous and functional cardiospheres that are responsive to external electrical stimulation. These findings drive clinical and industrial adaption of stem cell technology in tissue engineering and drug testing.
1 March 2020 in Materials Today Bio
Cell-laden hydrogel microcapsules enable the high-throughput production of cell aggregates, which are relevant for three-dimensional tissue engineering and drug screening applications. However, current microcapsule production strategies are limited by their throughput, multistep protocols, and limited amount of compatible biomaterials. We here present a single-step process for the controlled microfluidic production of single-core microcapsules using enzymatic outside-in cross-linking of tyramine-conjugated polymers. It was hypothesized that a physically, instead of the conventionally explored biochemically, controlled enzymatic cross-linking process would improve the reproducibility, operational window, and throughput of shell formation. Droplets were flown through a silicone delay line, which allowed for highly controlled diffusion of the enzymatic cross-linking initiator. The microcapsules' cross-linking density and shell thickness is strictly depended on the droplet's retention time in the delay line, which is predictably controlled by flow rate. The here presented hydrogel cross-linking method allows for facile and cytocompatible production of cell-laden microcapsules compatible with the formation and biorthogonal isolation of long-term viable cellular spheroids for tissue engineering and drug screening applications.
26 October 2023 in Advanced Healthcare Materials
3D cellular spheroids offer more biomimetic microenvironments than conventional 2D cell culture technologies, which has proven value for many tissue engineering applications. Despite beneficiary effects of 3D cell culture, clinical translation of spheroid tissue engineering is challenged by limited scalability of current spheroid formation methods. Although recent adoption of droplet microfluidics can provide a continuous production process, use of oils and surfactants, generally low throughput, and requirement of additional biofabrication steps hinder clinical translation of spheroid culture. Here, the use of clean (e.g., oil‐free and surfactant‐free), ultra‐high throughput (e.g., 8.5 mL min−1, 10 000 spheroids s−1), single‐step, in‐air microfluidic biofabrication of spheroid forming compartmentalized hydrogels is reported. This novel technique can reliably produce 1D fibers, 2D planes, and 3D volumes compartmentalized hydrogel constructs, which each allows for distinct (an)isotropic orientation of hollow spheroid‐forming compartments. Spheroids produced within ink‐jet bioprinted compartmentalized hydrogels outperform 2D cell cultures in terms of chondrogenic behavior. Moreover, the cellular spheroids can be harvested from compartmentalized hydrogels and used to build shape‐stable centimeter‐sized biomaterial‐free living tissues in a bottom‐up manner. Consequently, it is anticipated that in‐air microfluidic production of spheroid‐forming compartmentalized hydrogels can advance production and use of cellular spheroids for various biomedical applications.
16 April 2019 in Lab on a Chip
Exchangeable microfluidic nozzles enable the facile production of a wide variety of micromaterials using a single cleanroom-free manufactured microfluidic device.
13 August 2023 in Advanced Healthcare Materials
BZBarbara Zoetebier‐Liszka
+4
Transplantation of microencapsulated pancreatic cells is emerging as a promising therapy to replenish β‐cell mass lost from auto‐immune nature of type I diabetes mellitus (T1DM). This strategy intends to use micrometer‐sized microgels to provide immunoprotection to transplanted cells to avoid chronic application of immunosuppression. Clinical application of encapsulation has remained elusive due to often limited production throughputs and body's immunological reactions to implanted materials. This article presents a high‐throughput fabrication of monodisperse, non‐immunogenic, non‐degradable, immunoprotective, semi‐permeable, enzymatically‐crosslinkable polyethylene glycol‐tyramine (PEG‐TA) microgels for β‐cell microencapsulation. Monodisperse β‐cell laden microgels of ≈120 µm, with a shell thickness of 20 µm are produced using an outside‐in crosslinking strategy. Microencapsulated β‐cells rapidly self‐assemble into islet‐sized spheroids. Immunoprotection of the microencapsulated is demonstrated by inability of FITC‐IgG antibodies to diffuse into cell‐laden microgels and NK‐cell inability to kill microencapsulated β‐cells. Multiplexed ELISA analysis on live blood immune reactivity confirms limited immunogenicity. Microencapsulated MIN6β1 spheroids remain glucose responsive for 28 days in vitro, and able to restore normoglycemia 5 days post‐implantation in diabetic mice without notable amounts of cell death. In short, PEG‐TA microgels effectively protect implanted cells from the host's immune system while being viable and functional, validating this strategy for the treatment of T1DM.